tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ascletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
PremiumCompany AnnouncementsAscletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
1M ago
Ascletis Pharma Advances Acne Treatment with Pre-NDA Completion
Premium
Company Announcements
Ascletis Pharma Advances Acne Treatment with Pre-NDA Completion
2M ago
Ascletis Pharma Advances ASC35 for Obesity Treatment
Premium
Company Announcements
Ascletis Pharma Advances ASC35 for Obesity Treatment
2M ago
Ascletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
PremiumCompany AnnouncementsAscletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
3M ago
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
Premium
Company Announcements
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
3M ago
Ascletis Pharma’s ASC30 Shows Promise in Obesity Management
Premium
Company Announcements
Ascletis Pharma’s ASC30 Shows Promise in Obesity Management
3M ago
Ascletis Pharma’s Obesity Drug Candidates Show Promising Preclinical Results
PremiumCompany AnnouncementsAscletis Pharma’s Obesity Drug Candidates Show Promising Preclinical Results
4M ago
Ascletis Pharma Reports Reduced Losses and R&D Progress in Interim Results
Premium
Company Announcements
Ascletis Pharma Reports Reduced Losses and R&D Progress in Interim Results
4M ago
Ascletis Pharma’s ASC47 Shows Superior Efficacy in Obesity Treatment
Premium
Company Announcements
Ascletis Pharma’s ASC47 Shows Superior Efficacy in Obesity Treatment
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100